Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-24T22:56:34.785Z Has data issue: false hasContentIssue false
  • English
  • Français

Soluble Fas ligand (sFasL) as a predictor of reduction of general psychopathology in schizophrenia after antipsychotic treatment

Published online by Cambridge University Press:  23 March 2020

K. Szymona ,
H. Karakula-Juchnowicz ,
B. Zdzisinska ,
M. Flis ,
K. Kaławaj ,
W. Rosa  and
M. Kandefer-Szerszeń
K. Szymona*
Affiliation:
Medical University of Lublin, Mental Health Outpatient Clinic, Lublin, Poland
H. Karakula-Juchnowicz
Affiliation:
Medical University of Lublin, Department of Psychiatry, Psychotherapy and Early Intervention, Lublin, Poland
B. Zdzisinska
Affiliation:
Maria Curie-Skłodowska University in Lublin, Department of Virology and Immunology, Lublin, Poland
M. Flis
Affiliation:
Medical University of Lublin, Department of Clinical Neuropsychiatry, Lublin, Poland
K. Kaławaj
Affiliation:
Maria Curie-Skłodowska University in Lublin, Department of Virology and Immunology, Lublin, Poland
W. Rosa
Affiliation:
Lublin University of Technology, Department of Applied Mathematics, Lublin, Poland
M. Kandefer-Szerszeń
Affiliation:
Maria Curie-Skłodowska University in Lublin, Department of Virology and Immunology, Lublin, Poland
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Dysregulation of the apoptotic process is associated with the etiopathogenesis of schizophrenia, which is observed at the brain and peripheral blood levels. A significant negative correlation between the duration of the disease and serum sFasL concentration was demonstrated by other authors. It was shown that an increased rate of apoptosis is more pronounced in neuroleptic-free patients with the first-episode of schizophrenia than in patients with chronic disease.

Aim

Search for a predictor of good response to antipsychotic treatment based on the analysis of the sFasL plasma level and its relationship with clinical symptoms.

Methods

Fifty-three patients with chronic schizophrenia and 46 healthy individuals were enrolled in the study. The concentration of sFasL was measured by ELISA. Clinical assessments (PANSS, SANS, SAPS) and blood analyses were conducted three times: during the active phase of disease (at admission), after 4 weeks of pharmacotherapy, and after reaching remission.

Results

In the schizophrenia group, non-altered levels of sFasL (P = 0.1; U Mann-Whitney test), compared to the control, were detected at admission. The initial level of sFasL correlated negatively (r = −0.33; P = 0.04; Spearman's rank) with blood leukocyte count. Despite clinical improvement, no significant changes in the level of sFasL were observed. However, the sFasL level correlated negatively with the PANSS general psychopathology reduction after 4 weeks of pharmacotherapy (r = −0.7; P = 0.04) and after remission (r = −0.39; P = 0.026).

Conclusions

The results indicate a possible role of sFasL in apoptosis of blood leukocytes and suggest that the reduction of sFasL level can predict level of PANSS general psychopathology after antipsychotic treatment in schizophrenia.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
FC92
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S108
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.